Phase 1 study for people with Hypertension
Not yet recruiting Phase 1
This trial at a glance
Where this trial is running
| Site | City | State or country | Status at this site |
|---|---|---|---|
| Veritus | Melbourne | VIC | Status not stated |
voxsanity.com.au · trial sites from public registries · registry record synced 12 October 2026 · not medical advice
Who can join
The official eligibility criteria
Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.
Inclusion Criteria:
* Screening visit SBP from 110 to 139 mmHg and DBP \<90 mmHg based on the average of three consecutive measurements in a single visit via AOBPM
* Body mass index between 18.5 and 35 kg/m2, inclusive
* Untreated serum LDL-C ≥100 mg/dL (≥2.6 mmol/L).
* Absence of evidence or diagnoses of acute or chronic disease following a detailed medical and surgical history
* Female participants who are of childbearing potential must be willing to use two highly effective methods of contraception
* Able to participate, and willing to give written informed consent and to comply with the study restrictions\[S
Exclusion Criteria:
* Any active or chronic disease
* Confirmed SBP ≥140 mmHg or DBP ≥90 mmHg at Screening
* History of orthostatic hypotension, postural orthostatic tachycardic syndrome, unexplained dizziness, fatigue, pre-syncope, or syncope.
* Resting pulse rate \<50 or \>100 beats/min.
* Age ≥ 40 years and having a 10-year risk of ASCVD ≥ 7.5% based on the ASCVD Risk Estimator Plus (PREVENT™ mode) from the American College of Cardiology
* Participants with any risk factors or family history for QT or Fridericia-corrected QT interval (QTcF) prolongation or ECG abnormalities or any abnormality in the ECG that, in the opinion of the investigator, increases the risk of participating in the study will be excluded. Screening, Day 1, or pre-dose QTcF \< 300 msec or \> 450 msec for males and \> 470 msec for females.
* Clinically significant abnormalities on physical examination, vital signs, or laboratory test results during Screening or prior to admission to the study unit.
* Fasting triglyceride level ≥ 400 mg/dL (≥ 4.52 mmol/L).
* Estimated glomerular filtration rate (eGFR) \< 60 mL/min.
* Alanine aminotransferase (ALT) and/or total bilirubin \> 1.5 × Upper Limits of Normal (ULN). Aspartate aminotransferase (AST), alkaline phosphatase (ALP), or gamma glutamyl transferase (GGT) \> 2 × ULN. International normalized ratio (INR) above the upper bound of the normal reference range (as per the local laboratory reference range) at Screening.
Dates on the record
Results, publications and the official record
- No results are posted on the official record yet.
- No publications are listed on the official record yet.
- Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.
Sources and dates
- ClinicalTrials.gov – the record this page reformats
- ClinicalTrials.gov processing date: 5 October 2026.
- This page last checked by Voxsanity: 12 October 2026.
Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.
Not medical advice.
Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.
Letter for your doctor
A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.